A study published in the Journal of Internal Medicine has uncovered a high prevalence of metabolic syndrome in adults with moderate chronic kidney disease, and found that metabolic syndrome increases their risk of premature death and cardiovascular problems.
Among 5,110 adults in Germany who had chronic kidney disease, 64.3% also had metabolic syndrome. During 6.5 years of follow-up, 605 patients died and 650 experienced major cardiovascular events (such as heart attacks and strokes). Patients with metabolic syndrome had a 26% higher risk of dying and a 48% higher risk of experiencing cardiovascular events. The risk increased steadily with a growing number of metabolic syndrome components, such as increased waist circumference, blood sugar levels, triglycerides, and blood pressure, and decreased HDL cholesterol.
“Although our study uncovered a shockingly high frequency of metabolic syndrome in this high-risk patient group, there’s a motivating message for our patients: each metabolic syndrome component avoided might considerably decrease the risk for a cardiovascular endpoint or premature death,” said senior author Florian Kronenberg, MD,
of the Medical University of Innsbruck, in Austria.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/joim.13355
About Journal
JIM – The Journal of Internal Medicine is an international peer-reviewed scientific journal in continuous publication since 1863. JIM publishes original work in clinical science from bench to bedside covering a broad field of internal medicine and its subspecialties. JIM features original articles, reviews, brief reports and research letters.
About Wiley
Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at Wiley.com, like us on Facebook and follow us on Twitter and LinkedIn.